Institutional members access full text with Ovid®

Share this article on:

Emerging therapeutic agents to lower lipoprotein (a) levels

Kolski, Brian; Tsimikas, Sotirios

doi: 10.1097/MOL.0b013e3283598d81
THERAPY AND CLINICAL TRIALS: Edited by Anton F. Stalenhoef and John Kastelein

Purpose of review Recent epidemiological and genetic studies have suggested that lipoprotein (a) [Lp(a)] is a causal mediator of cardiovascular disease (CVD). There is now interest in evaluating Lp(a) as a therapeutic target. This review will summarize emerging therapeutic agents to lower Lp(a).

Recent findings Apheresis is the most efficacious method to lower Lp(a). Currently, there are no approved drugs to specifically lower Lp(a). However, recent data has demonstrated that Lp(a) can be significantly lowered, along with reductions in other apolipoprotein B-100 (apoB) containing lipoproteins, with antisense oligonucleotides to apoB, monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, cholesterol ester transfer protein inhibitors, and thyromimetics. The farnesoid X receptor/fibroblast growth factor axis and interleukin-6 also influence Lp(a) levels and may be targets of therapy. Finally, specific apolipoprotein (a) [apo(a)] inhibitors apo(a) have been developed and reduce apo(a) mRNA and protein levels up to 86% without significantly affecting other lipoproteins.

Summary Lp(a) remains the last major lipoprotein disorder without any specific therapy. With the strong and accumulating data on its role as a causal risk factor for CVD, a rationale exists to develop novel agents to reduce Lp(a) and test the hypothesis that this will lead to reduced CVD events.

Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, California, USA

Correspondence to Sotirios Tsimikas, Vascular Medicine Program, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0682, USA. Tel: +1 (858) 534 6109; e-mail:

Copyright © 2012 Wolters Kluwer Health, Inc. All rights reserved.